Similarly, the donanemab trial found an average annual progression in CDR‐SB for the placebo group of 1.65 (based on the published 76‐week ∆CDR‐SB of 2.42), with treatment decreasing this progression by 0.48 (95% 0.31–0.65, based on the published 76‐week decrease in ∆CDR‐SB of 0.7) in the combined population. 2 The donanenab trial also reported a differential effect of treatment based on the measured tau PET levels: among those with low/medium tau PET, the placebo group had an average annual CDR‐SB progression of 1.29, with donanemab decreasing progression by 0.46 (95% CI 0.27–0.65), and among those with high tau PET, the placebo group had an average annual CDR‐SB progression of 2.29 with donanemab treatment decreasing progression by 0.47 (95% CI 0.140.82). Assuming that these effects are constant over the course of treatment, those with baseline CDR‐SB = 2 if treated with donanemab would be expected to have an additional 8 months of independence in IADLs (95% CI 5–12 months, Figure 3B) in the combined population, an additional 13 months of independence in IADLs for the low/medium tau PET group (95% CI
